KALOBIOS PHARMACEU COM USD0.001(POST REV SPLT) (KBIO)

3.55
0.05 1.43
NASDAQ
Prev Close 3.50
Open 3.50
Day Low/High 3.50 / 3.61
52 Wk Low/High 0.44 / 45.82
Volume 6.81K
Exchange NASDAQ
Shares Outstanding 14.90B
Market Cap 52.14M
Div & Yield N.A. (N.A)

Latest News

KALOBIOS PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

KALOBIOS PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...

Investor Alert: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In KaloBios Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

Investor Alert: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In KaloBios Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf...

KaloBios Pharmaceuticals, Potash and Radian: Doug Kass' Views

KaloBios Pharmaceuticals, Potash and Radian: Doug Kass' Views

Doug Kass shares his views on Potash, Radian and oil, and revisits his prediction about KaloBios.

Stocks Slip on 2016 Outlook of Middling Economic Growth

Stocks Slip on 2016 Outlook of Middling Economic Growth

As Wall Street prepares to close out 2015 much where it started, investors looked to the year ahead to determine direction on the second-last day of trading.

Energy Lags Wall Street as Crude Oil Spirals Lower

Energy Lags Wall Street as Crude Oil Spirals Lower

Stocks move slightly lower as another selloff in crude oil prices hits the energy sector.

KaloBios Pharmaceuticals (KBIO) Files For Bankruptcy, Stock Delisted From Nasdaq

KaloBios Pharmaceuticals (KBIO) Files For Bankruptcy, Stock Delisted From Nasdaq

KaloBios Pharmaceuticals (KBIO), the drugmaker that fired CEO Martin Shkreli less than two weeks ago, filed for Chapter 11 bankruptcy on Tuesday.

Stocks Fall on Global Growth Concerns

Stocks Fall on Global Growth Concerns

Stocks pull back on Wednesday morning as crude oil returns to a level below $37 a barrel.

Dec. 30 Premarket Briefing: 10 Things You Should Know

Dec. 30 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are dipping somewhat Wednesday as oil prices weaken, despite a strong showing in the markets on Tuesday.

Crude Oil Prices Retreat Back to 11-Year Lows on Supply Worries

Crude Oil Prices Retreat Back to 11-Year Lows on Supply Worries

The weak outlook for oil prevails, and oil prices are sliding back toward an 11-year low.

Dec. 24 Premarket Briefing: 10 Things You Should Know

Dec. 24 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are pointing lower in what's expected to be a quiet trading session ahead of the Christmas holiday.

European Shares Open Higher as Oil Prices Rebound

And four other things you need to know now.

EQUITY ALERT: Rosen Law Firm Announces The Filing Of A Securities Class Action Lawsuit Against KaloBios Pharmaceuticals, Inc. - KBIO

EQUITY ALERT: Rosen Law Firm Announces The Filing Of A Securities Class Action Lawsuit Against KaloBios Pharmaceuticals, Inc. - KBIO

Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of KaloBios Pharmaceuticals, Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Claims Of Possible Securities Fraud By KaloBios Pharmaceuticals, Inc. And Certain Officers And Directors

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Claims Of Possible Securities Fraud By KaloBios Pharmaceuticals, Inc. And Certain Officers And Directors

Levi & Korsinsky, LLP announces that it has commenced an investigation of KaloBios Pharmaceuticals, Inc.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces An Investigation Of Claims Against KaloBios Pharmaceuticals, Inc. And Strongly Encourages Investors With Losses In Excess Of $200,000 To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces An Investigation Of Claims Against KaloBios Pharmaceuticals, Inc. And Strongly Encourages Investors With Losses In Excess Of $200,000 To Contact The Firm

Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by KaloBios Pharmaceuticals, Inc.

Apple, KaloBios and Blackstone/GSO Strategic Credit Fund: Doug Kass' Views

Apple, KaloBios and Blackstone/GSO Strategic Credit Fund: Doug Kass' Views

Doug Kass shares another reason he's shorting Apple and why KaloBios could hit $0.

Shkreli 'Was Running Turing Like a Hedge Fund'

Shkreli 'Was Running Turing Like a Hedge Fund'

Martin Shkreli resigned as chief executive officer of Turing Pharmaceuticals Friday following his arrest on charges of securities fraud.